AN2 Therapeutics
a day phase dose ranging study of oral supports once daily dose for patients with treatment refractory mac lung disease phase design and results once daily dose achieved exposures suggesting high probability of target attainment for treatment of mac lung disease and was well tolerated through day so i generally an therapeutics | AN2 Therapeutics
Deck date
August 2022
Slide
16 of 25
Similar slides by AN2 Therapeutics
IPO
March 2022
Related slides by other companies
Investor Presentation
August 2023
Investor Presentation
December 2023
Results
November 2020
Investor Presentation
March 2023
Other recent decks by AN2 Therapeutics
IPO
March 2022
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io